Drug intelligence / Profile preview

BG-P-TAT

Development stage: Preclinical
Lead developer: NanoPharmaceuticals
Administration: Subcutaneous, Intravenous, Intranasal, Intraperitoneal, Oral, Intrathecal

Overview

BG-P-TAT is a molecularly targeted macromolecule being developed by NanoPharmaceuticals for the treatment of neuroblastoma and other neuroendocrine cancers. It is designed to dual-target the thyrointegrin αvβ3 receptor and the norepinephrine transporter (NET), both of which are frequently overexpressed in neuroendocrine-derived malignancies. By engaging these specific cell-surface markers, BG-P-TAT aims to enhance the specificity and efficacy of therapeutic delivery to cancer cells. The candidate is currently in the preclinical stage of development.

Targets

NET (Norepinephrine Transporter)αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on BG-P-TAT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-P-TAT.

Explore the full profile